🔗 Share this article

Given that America undertakes unprecedented adjustments to its vaccination schedules, an unexpected name has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who initially gained attention by casting doubt on COVID-19 vaccinations during the global health crisis and has focused upon alleged deaths following COVID-19 immunization in her short tenure at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Schedule

Agency leaders planned to unveil radical changes to the pediatric immunization program recently, bringing the US with the Danish national calendar, sources say – a significant shift that would put the US out of step with many the world with little proof for public health gain. This reveal has been pushed back until the coming year.

Rather than the top vaccines chief, Tracy Beth Høeg is set to address the audience at the meeting. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth individual to head the center this calendar year.

A Shift at the Agency

The acting appointment could signify a strengthened alliance between the drug and vaccine branches as Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

Høeg has often pushed for halting certain pediatric immunization guidelines in the US in order to be more like Denmark, a nation with universal health coverage and a population approximately the size of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – typically the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Questions Over Expertise

Dr. Høeg has no apparent track record in pharmaceutical research, regulation or leadership, which has been typical for past directors of the biologics center. She has served at the FDA as a key advisor to the agency head and CBER since spring.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in leading a major agency. She has no expertise in industry regulation.”

Past directors of the center would “grasp legal statutes and the science of pharmaceutical innovation”, said Janet Woodcock. “Clearly, she doesn’t have the type of experience that former directors who ran the center have had.”

This division has an vast portfolio at the agency, she stated.

“Everybody just pays attention on the new drug program, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and so forth, and each of these need to be managed,” she noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative element to the position, which oversees more than 5,000 personnel. “It is a massive management job, if you execute it properly,” the former official concluded.

Agency Reaction and Contentious Policies

In response to questions about Høeg’s qualifications and whether this selection indicates more teamwork among agency officials on vaccines, a press secretary stated that the “concerns rely on flawed presumptions”.

“Her experience aligns with the responsibilities of her role,” the representative explained, noting the months Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg takes over the commissioner’s recently launched priority voucher program, a contentious expedited therapy clearance system that apparently concerned her former heads. “By what process are these drugs being selected for this fast-track system? Who is making the calls?” Dr. Howard asked. “There is a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he remarked, “the agency looks to be trending towards more relaxed regulations of pharmaceuticals, except for immunizations.”

Public Past Work on Immunizations

Concerning immunizations, Høeg has a clearer, if problematic, track record, critics observe. She authored a research paper using unconfirmed crowd-sourced reports to estimate the incidence of myocarditis following Covid immunization. She counseled the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are riskier than they are.

Part of her “policy goals” for the new federal leadership included changing guidelines for novel immunizations and discontinuing “non-essential” vaccines, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has according to sources floated the idea of excluding teenage boys from obtaining Covid vaccinations.

“She’s an all-around dogmatist who commences with her beliefs and tailors the evidence to accommodate the science in a highly misleading, untruthful manner,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|